Treace Medical (TMCI) CEO buys 50,000 shares in open-market trade

Rhea-AI Filing Summary

Treace Medical Concepts Chief Executive Officer John T. Treace purchased 50,000 shares of common stock in an open-market transaction on June 1, 2026 at a weighted average price of $3.5583 per share, with individual prices ranging from $3.51 to $3.60.

Following this purchase, he directly holds 7,323,833 shares of common stock, which includes 542,784 restricted stock units. He also reports additional indirect holdings through various trusts and his spouse, while expressly disclaiming beneficial ownership of those indirectly held shares.

Insider Trade Summary

Net Buyer: 50,000 shares ($177,915)

Net Buy 5 txns

Insider Treace John T.

Role Chief Executive Officer

Bought 50,000 shs ($178K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	50,000	$3.5583	$178K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 7,323,833 shares (Direct, null); Common Stock — 1,605,000 shares (Indirect, By spouse)

Footnotes (1)

1. The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $3.5100 to $3.6000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. Includes 542,784 restricted stock units. The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee. The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.

Key Figures

Shares purchased: 50,000 shares Weighted average price: $3.5583 per share Price range: $3.51–$3.60 per share +5 more

8 metrics

Shares purchased 50,000 shares Open-market purchase on June 1, 2026

Weighted average price $3.5583 per share Price for 50,000-share open-market purchase

Price range $3.51–$3.60 per share Range of individual trade prices for purchased shares

Direct holdings after purchase 7,323,833 shares Common stock directly owned by CEO after transaction

Restricted stock units included 542,784 RSUs Restricted stock units included in direct holdings

Indirect holding as co-trustee 408,816 shares Common stock held in trust where CEO is co-trustee

Indirect holding as trustee 1,839,063 shares Common stock held in trust where CEO is trustee

Spouse-related indirect holdings 1,471,250 and 1,605,000 shares Common stock held by spouse and spouse as trustee

Key Terms

open-market purchase, weighted average purchase price, restricted stock units, beneficial ownership, +1 more

5 terms

open-market purchase financial

"Purchase in open market or private transaction"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average purchase price financial

"The price reported in Column 4 is a weighted average purchase price."

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

restricted stock units financial

"Includes 542,784 restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

beneficial ownership financial

"The Reporting Person disclaims beneficial ownership of shares held by his wife"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

co-trustee of a trust financial

"As co-trustee of a trust"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Treace John T.

(Last) (First) (Middle)

C/O TREACE MEDICAL CONCEPTS, INC.

100 PALMETTO PARK PLACE

(Street)

PONTE VEDRA FLORIDA 32081

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TREACE MEDICAL CONCEPTS, INC. [ TMCI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		P		50,000	A	$3.5583(1)	7,323,833(2)	D
Common Stock								1,605,000(3)	I	By spouse
Common Stock								1,471,250(3)	I	By spouse as trustee of a trust
Common Stock								1,839,063(4)	I	As trustee of a trust
Common Stock								408,816(4)	I	As co-trustee of a trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $3.5100 to $3.6000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

2. Includes 542,784 restricted stock units.

3. The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee.

4. The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.

	/s/ Lisa Taylor as Attorney-in-fact for John Treace	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did TMCI CEO John T. Treace do in this Form 4 filing?

John T. Treace reported buying 50,000 shares of Treace Medical Concepts common stock in an open-market transaction. This increases his direct equity stake and reflects additional personal capital committed at prices between $3.51 and $3.60 per share.

How many TMCI shares did the CEO buy and at what price?

He bought 50,000 common shares at a weighted average price of $3.5583 per share. The shares were acquired in multiple trades, with individual transaction prices ranging from $3.51 to $3.60, as detailed in the filing’s footnote.

What are John T. Treace’s direct TMCI holdings after this transaction?

After the purchase, John T. Treace directly owns 7,323,833 shares of Treace Medical Concepts common stock. This figure includes 542,784 restricted stock units, which typically represent share-based compensation that may settle in stock over time.

What does the filing say about restricted stock units for TMCI’s CEO?

The filing states that Treace’s direct holdings include 542,784 restricted stock units. Restricted stock units are share-based awards that generally vest over time, potentially converting into common shares and further aligning executive compensation with shareholder outcomes.

Does the TMCI CEO report any indirect share ownership in this filing?

Yes. The filing lists indirect holdings through trusts where he is trustee or co-trustee and through his spouse, directly and via trusts. However, he expressly disclaims beneficial ownership of those indirectly held shares, limiting how they are attributed to him economically.

Was the TMCI CEO’s share purchase a market transaction?

Yes. The transaction is coded as an open-market purchase. A footnote explains that the reported price is a weighted average across multiple trades executed within a $3.51 to $3.60 per share range on the transaction date.